HCS Pharma: Pioneering In Vitro Innovation with BIOMIMESYS®

Company Overview

HCS Pharma is a French biotechnology company founded in 2014 and based in Loos, near Lille. It was established by Dr. Nathalie Maubon and Julian Bursztyka with a vision to transform in vitro research and development. The company specializes in high-content and high-throughput cell imaging, offering advanced tools for preclinical drug discovery.

BIOMIMESYS®: A Breakthrough in 3D Cell Culture

At the heart of HCS Pharma’s innovation is BIOMIMESYS®—a unique 3D extracellular matrix technology designed to mimic the natural microenvironment of human tissues. Unlike traditional 2D cell culture systems, BIOMIMESYS® enables more realistic, tissue-specific in vitro models, which enhance the predictive power of drug testing and reduce the need for animal models.

Composition and Customization

BIOMIMESYS® is made from natural components such as hyaluronic acid, collagens, and adhesion proteins. The matrix is developed through a patented green chemistry process that preserves the integrity and biological functionality of its materials. It can be customized to match the biochemical and mechanical properties of specific tissues, allowing the development of organ-specific models such as liver organoids and tumor tissues.

Global Collaborations and Applications

HCS Pharma extended the use of BIOMIMESYS® through international partnerships, particularly in Asia. Collaborative projects in Japan, Singapore, and Taiwan have explored its potential in regenerative medicine, dermocosmetic testing, and personalized therapy development. These initiatives aimed to provide more accurate and ethical testing models across pharmaceutical, nutraceutical, and cosmetic industries.

Acheter Ozempic en ligne sans ordonnance : Guide complet pour 2025

HCS Pharma – R&D programs and partnerships

We are involved in amazing projects to improve medical and biological science, thanks to partners all around the world. Click on a project to get more information.